BI 767551 intravenous

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

COVID-19

Phase 2

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

TerminatedNCT04822701

Boehringer IngelheimCOVID-19

Start: 2021-04-21End: 2021-10-04Updated: 2022-07-28

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

WithdrawnNCT04894474

Boehringer IngelheimCOVID-19

Start: 2021-06-17End: 2022-07-24Updated: 2021-11-08